PRTN3 and rheumatoid arthritis: The ability of abatacept to suppress the ACPA immune complex-induced production of inflammatory cytokines/chemokines from monocytes may also explain why the clinical efficacy of abatacept was more prominent in ACPA-positive RA patients than in ACPA-negative patients, and RA patients with higher ACPA titers showed better responses to abatacept [24].